A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)
In our study, guselkumab provided significant long-term effectiveness and safety in patients partially responsive to ustekinumab, improving both PASI score and site-specific PGA and confirming its potential use for patients with psoriasis switching from ustekinumab.
Authors
- Marco Campoli (ORCID: https://orcid.org/0000-0002-3843-0108)
- Angelo Valerio Marzano (ORCID: https://orcid.org/0000-0002-2258-8357)
- Federica Mola
- Anna Minuti
- Piergiorgio Malagoli (ORCID: https://orcid.org/0000-0002-6181-6922)
- Ruggero Cascio Ingurgio (ORCID: https://orcid.org/0009-0000-1438-9553)
- Antonio Costanzo (ORCID: https://orcid.org/0000-0001-9697-2557)
- Mario Valenti (ORCID: https://orcid.org/0000-0001-9140-9263)
- Luciano Ibba (ORCID: https://orcid.org/0000-0002-7876-4866)
- Andrea Carugno (ORCID: https://orcid.org/0000-0002-8231-2205)
- Nicola Zerbinati (ORCID: https://orcid.org/0000-0003-2177-9677)
- Alessandra Narcisi (ORCID: https://orcid.org/0000-0002-1938-8581)
- Francesca Maria Gaiani (ORCID: https://orcid.org/0009-0003-7613-4451)
- Carlo Giovanni Carrera
- Davide Strippoli
Institutions
- University of Insubria (IT)
- Humanitas University (IT)
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- IRCCS Policlinico San Donato (IT)
- Alessandro Manzoni Hospital (IT)
- Azienda Socio Sanitaria Territoriale Lariana (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-10-13
- DOI
- https://doi.org/10.1007/s13555-024-01270-5
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Celgene
- Galderma
- LEO Pharma
- UCB Pharma
- Cilag